Intravacc, EpiVax partner for COVID-19 vaccine

By The Science Advisory Board staff writers

June 2, 2020 -- Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer membrane vesicle (OMV) technology platform.

Outer membrane vesicles (OMVs) are spherical particles with intrinsic adjuvating properties. Empty OMVs can be loaded with antigens of choice via genetic engineering.

The joint venture will combine Intravacc's immunogenic OMV delivery platform with synthetically produced COVID-19 epitopes designed and optimized by EpiVax's immunoinformatics tools that generate safe and effective T-cell responses against SARS-CoV-2.

Preclinical studies to select the best peptide candidates have already begun. Intravacc will utilize its in-house pilot-scale facility for good manufacturing practices production of the OMV-peptide vaccine for phase I clinical studies, which are expected to begin in fourth quarter 2020, according to the firm.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here